Efficacy and safety of laparoscopic radical resection following neoadjuvant therapy for pancreatic ductal adenocarcinoma: A retrospective study

Table 1 General data of the patients

Variables
Sex, n (%)
Male	7 (46.7)
Female	8 (53.3)
Age (yr)	55.53 ± 7.89
Body mass index, kg/m2	22.29 ± 2.94
Resectability, n (%)
Borderline resectable (n)	7 (46.7)
Advanced pancreatic cancer (n)	8 (53.3)
ASA grade, n (%)
I	13 (86.7)
II	2 (13.3)
Chemotherapy regimen, n (%)
AG	13 (86.7)
Modified FOLFIRINOX	2 (13.3)
ECOG score, n (%)
0	11 (73.3)
1	2 (13.35)
2	2 (13.35)
Chemotherapy cycle	4 ± 1
Response to chemotherapy
PR	15 (100%)
CR	0
Tumor diameter before chemotherapy (cm)	4.17 ± 1.40
Tumor diameter before surgery (cm)	3.03 ± 1.13
Tumor regression (%)	28.40 ± 9.71
CA19-9 level before chemotherapy (U/mL)	736.25 (8.44-1200.00)1
CA19-9 level before surgery (U/mL)	51.85 (4.81-341.3)1
Decrease in CA19-9 level (%)	57.07 ± 32.07
Total count of CTCs before chemotherapy (n)	16 (13-26)1
Total count of CTCs before surgery (n)	7.13 ± 2.88
Decrease in the total number of CTCs (%)	65.33 ± 12.09

¹Data are presented as the mean ± SD or median (interquartile range).

ASA: American Society of Anesthesiologists; AG: Nab-paclitaxel + gemcitabine; modified FOLFIRINOX: Oxaliplatin + leucovorin + irinotecan + fluorouracil; CTC: Circulating tumor cells; CA19-9: Carbohydrate antigen 19-9; PR: Partial response; ECOG: Eastern Cooperative Oncology Group; CR: Complete response.